Cytomed therapeutics ltd GDTC.US 總覽分析
GDTC 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
GDTC 近期報酬表現
3.02%
Cytomed therapeutics ltd
1.99%
同產業平均
-0.64%
S&P500
與 GDTC 同產業的標的表現
- GTBP Gt biopharma inc價值 3 分趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
GDTC 公司資訊
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The CTM-GDT product candidate consists of expanded allogeneic gamma delta T cells.